Content
02/15/2024
South San Francisco, CA USA
Freenome
completed $254 million Venture Round funding. Investors include
Roche Venture Fund (lead), Sands Capital, Perceptive Advisors, Polaris Partners, Andreessen Horowitz, BrightEdge, Artis Ventures, Bain Capital Ventures, Eventide Asset Management, ArrowMark Partners, Pura Vida Investments, Cormorant Asset Management, ARK Invest, RA Capital Management, DCVC, Intermountain Ventures.
About
Freenome is a high-growth biotech company on a mission since 2014 to create tools that empower everyone to prevent, detect, and treat their disease.
To achieve this mission, Freenome is developing next-generation blood tests to detect cancer in its earliest, most treatable stages using our multiomics platform and machine learning techniques. Our first blood test will detect early-stage colorectal cancer and advanced adenomas.
We have raised more than $1.1 billion from leading investors like Perceptive Advisors, RA Capital Management, Roche Venture Fund, Kaiser Permanente, Novartis and the American Cancer Society’s BrightEdge Ventures.
A ‘Freenomer’ is a mission-driven employee who is fueled by the opportunity to make a positive impact on patients' lives, who thrives in a culture of respect and cross collaboration, and whose work makes a significant impact on the company and their career.
Startup
Sector:
Biotech
Download StockFan App
Ad
Stock market data, news and community, all integrated.
Features include real time stock quotes, interactive charts, technical signals, institutional & insider ownerships, stock screener, ETF rankings, SEC filings, press releases, videos, earnings calendar, social media posts, group chats.
